It is time to develop more active treatments in the early-disease setting that actually eradicate ER-positive breast cancer before new mutations and secondary resistance have a chance to develop. In this regard, standard chemotherapy is not the answer. (Source: Cancer Network) read more..
SubQ Herceptin Equivalent to IV Delivery (CME/CE)
(MedPage Today) -- A subcutaneous form of trastuzumab demonstrated activity and pharmacokinetics comparable to intravenous administration in breast cancer patients who received the agent before surgery, trial results showed. (Source: MedPage Today Hematology/Oncology) read more..
Highs and Loos
Since I last wrote it’s been a busy time, and I’ve been meaning to catch up, especially about BlogHer. It would be challenging to squeeze everything into one post about such a BIG event. So this is about something….smaller. The back story started before I got there, when I posted a piece on the Huffington [...]No related posts. read more..
No comments:
Post a Comment